{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T18:38:57Z","timestamp":1648838337200},"reference-count":8,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutical Development and Technology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.3109\/10837450.2012.680598","type":"journal-article","created":{"date-parts":[[2012,4,27]],"date-time":"2012-04-27T09:39:29Z","timestamp":1335519569000},"page":"535-543","source":"Crossref","is-referenced-by-count":2,"title":["New immediate release formulation for deterring abuse of methadone"],"prefix":"10.1080","volume":"18","author":[{"given":"A. O.","family":"Betancourt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Gosselin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. K.","family":"Vinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2012,4,27]]},"reference":[{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11926-008-0003-z","volume":"10","author":"Katz N","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1111\/j.1526-4637.2009.00672.x","volume":"10","author":"Webster L","year":"2009","journal-title":"Pain Med"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.2165\/11537940-000000000-00000"},{"key":"CIT0012","unstructured":"FDA, Guidance for Industry. Dissolution Testing of Immediate Release Solid Oral Dosage Forms. Rockville, MD: U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 1997."},{"key":"CIT0013","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Guideline Q 1 A (R2): Stability testing of new drug substances and products. Geneva, Switzerland: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use, 2003."},{"key":"CIT0014","unstructured":"The Merck Index, 10th Ed., editor M., Windholz, Rathway, N.J.: Merck &Co., Inc., 1983."},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1213\/00000539-197603000-00027","volume":"55","author":"Benson DW","year":"1976","journal-title":"Anesth Analg"},{"key":"CIT0016","unstructured":"Rowe RC, Sheskey PJ, Owen SC, eds. Handbook of pharmaceutical excipients. 5th ed., 2006."}],"container-title":["Pharmaceutical Development and Technology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/10837450.2012.680598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T21:25:25Z","timestamp":1561670725000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.3109\/10837450.2012.680598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,27]]},"references-count":8,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,1,14]]},"published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.3109\/10837450.2012.680598"],"URL":"https:\/\/doi.org\/10.3109\/10837450.2012.680598","relation":{},"ISSN":["1083-7450","1097-9867"],"issn-type":[{"value":"1083-7450","type":"print"},{"value":"1097-9867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,27]]}}}